Grant Life Sciences, Inc. (fka GLIF)

[RULiquid]

(BSNS WIRE) Grant Life Sciences Appoints Dr. Indira R. Pottathil as Director
f International Marketing; Will Oversee Expansion int
Grant Life Sciences Appoints Dr. Indira R. Pottathil as Director of Internationa
Marketing; Will Oversee Expansion into Asian Markets

Health Editors

LOS ANGELES--(BUSINESS WIRE)--Jan. 30, 2006--
Grant Life Sciences Inc. (OTC Bulletin Board: GLIF)
announced today the appointment of the Company's first Director of
International Marketing: Indira R. Pottathil, Ph.D.
Since 1996, Dr. Pottathil has served as Vice President of Research
& Development at biotechnology company AccuDx Corp., where she managed
compliance efforts as well as development and production of in vitro
diagnostic products. Dr. Pottathil began her career at the University
of Bombay's Cancer Research Institute, where she was a Senior
Scientist for six years. More recently, she was employed for five
years as an Information Scientist with Schering Plough. She earned her
doctorate in Applied Biology at the University of Bombay. In addition,
Dr. Pottathil served as a Postdoctoral Research Associate at The
Jackson Laboratory (Bar Harbor, Maine) and was a Postdoctoral Fellow
at Duke University.
"Dr. Pottathil is a very important addition to our management
team," said Dr. Hun-Chi Lin, President and Chief Scientist at Grant
Life Sciences. "One of her primary responsibilities will be to expand
our capacity to serve various Asian markets. We already have begun
generating revenues from sales in Asia of our rapid tests for Malaria
and Dengue Fever. These products, along with rapid tests for HIV-1 and
HIV-2 that also were acquired last year from AccuDx, represent an
impressive product portfolio. We are very excited to have Dr.
Pottathil on board to drive new-business development for Grant Life
Sciences in Asia."
AccuDx Corp., based in La Jolla, Calif., was founded by Ravi
Pottahil, Ph.D., one of the world's leading authorities in the field
of HIV/AIDS diagnostics and therapeutics. Under the agreement with
AccuDx, Grant Life Sciences controls the exclusive rights to AccuDx's
rapid tests, as well as AccuDx's proprietary colloidal gold reagent.
In addition, the agreement established the right for Grant Life
Sciences to manufacture these products in AccuDx's
'maquiladora'-modeled contract facility in Tijuana, Mexico, which is
registered with the FDA and is ISO 9002-certified. Dr. Ravi Pottahil
is assisting Grant Life Sciences in expanding its product line to
include rapid tests for Hepatitis, Rubella, and other common diseases.

About Grant Life Sciences Inc.

Grant Life Sciences Inc. develops products to improve the
efficiency of detecting and diagnosing cervical cancer, including a
sensitive, reliable, non-invasive, point-of-care test. The diagnostic
assay being developed by the Company has initial clinical validation
indicating superior sensitivity and specificity in detecting cervical
cancer and its precursors, a disease that kills in excess of 300,000
women annually. Currently there are more than 120 million cervical
screening tests administered annually in the U.S. and Europe. More
than 120 million eligible women 20+ years old in developed nations
still do not get Pap smears, and globally more than 1.7 billion over
the age of 20 have never been checked due to cultural, religious or
economic reasons. Further information is available at:
www.grantlifesciences.com.

Forward-Looking Safe Harbor Statement

With the exception of historical information, the matters
discussed in this press release are "forward-looking statements" that
involve a number of risks and uncertainties. The actual future results
of Grant Life Sciences could differ significantly from those
statements. Factors that could cause actual results to differ
materially include risks and uncertainties such as the inability to
finance the company's operations or expansion, inability to hire and
retain qualified personnel, changes in the general economic climate,
including rising interest rates and unanticipated events such as
terrorist activities, results of clinical trials, and market
acceptance of the Company's products. In some cases, "forward-looking
statements" can be identified by terminology such as "may," "will,"
"should," "expect," "plan," "anticipate," "believe," "estimate,"
"predict," "potential" or "continue," or other comparable terminology.
Although Grant Life Sciences believes that the expectations reflected
in the "forward-looking" statements are reasonable, such statements
should not be regarded as a representation by the Company, or any
other person, that such "forward-looking statements" will be achieved.
Grant Life Sciences undertakes no duty to update any of the
"forward-looking statements," whether as a result of new information,
future events or otherwise. In light of the foregoing, readers are
cautioned not to place undue reliance on such "forward-looking
statements." For further risk factors associated with our Company,
review our SEC filings.



KEYWORD: NORTH AMERICA CALIFORNIA UNITED STATES
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY INFECTIOUS DISEASES MEDICAL DEVICES ONCOL
GY PERSONNEL
SOURCE: Grant Life Sciences


CONTACT INFORMATION:
Grant Life Sciences
Don Rutherford, CFO
949-521-1232

*** end of story ***